Broadcast

e-SPACE CRM 2026 – Day Two

Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira

Broadcast

e-SPACE CRM 2026 – Day One

Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira

About

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Visit our Heart Failure Management Hub to discover a range of educational content to facilitate the use of SGLT-2 inhibitors and other guideline directed medical therapies as foundational treatment for HF.

Articles

Understanding the Role of GLP-1 RAs in the Treatment of HF

Published:

14 August 2025

Citation:

Cardiac Failure Review 2025;11:e19.

Hyperkalaemia in Acute Heart Failure: An Asian Population Study

Published:

30 June 2025

Citation:

Journal of Asian Pacific Society of Cardiology 2025;4:e20.

SGLTi and GLP-1 in HF

Published:

13 May 2025

Citation:

US Cardiology Review 2025;19:e12.

Obesity, Cardiac MRI Structure and Non-ischaemic Cardiomyopathy

Published:

09 May 2025

Citation:

Cardiac Failure Review 2025;11:e10.